Robert Paris | VP, Therapeutic Area Head, Latent Viruses

Robert Paris, VP, Therapeutic Area Head, Latent Viruses, Moderna

Robert Paris is VP, Therapeutic Area Head, Infectious Diseases at Moderna where he leads clinical development for its latent virus portfolio of vaccines include cytomegalovirus, herpes zoster, genital herpes, and Epstein-Barr virus programs as well as Translational Medicine studies. He initially joined Moderna in 2020 as Head, Translational Medicine and Early Development.  Prior to joining Moderna, he was Senior Director for Early Clinical Development at GSK Vaccines in the US, where he was focused on the early clinical development of vaccines for viral diseases. He has over 20 years’ experience in infectious diseases research and vaccine development and spent most of his early career in the US Army conducting malaria and HIV research. He has held academic appointments at the University of Maryland and the Uniformed Services University of Health Sciences; is board certified in Internal Medicine and Infectious Diseases and is a Fellow of the American College of Physicians and Infectious Diseases Society of America.


Day 2 - Wednesday 30th October @ 17:00

The Evolving Definition of Protection: Progress and Prospects in Therapeutic Vaccines & Immune Modulation

-      The evolving landscape of what constitutes a vaccine; exploring therapeutic vaccines and the distinction between prophylactic and therapeutic approaches

-      How well do we understand the immune system to be able to manipulate it for therapeutic uses?

-      Updates on therapeutic vaccine development

-      Future prospects for therapeutic vaccines & immune modulation

Senior Representative, BioNTech - TBC

last published: 10/Jun/24 12:45 GMT

back to speakers